Sofie Biosciences, a leader in the field of PET imaging, and PerkinElmer Inc., a global leader focused on the health and safety of people and the environment, have entered into an agreement in which PerkinElmer will exclusively commercialize and sell preclinical Positron Emission Tomography (PET) – X-Ray and 3-dimensional Computed Tomography (CT) imaging systems developed by, or in conjunction with, Sofie Biosciences.

PET imaging is an essential preclinical research tool in understanding the biology of disease, biological impact of drugs, and clinical translation. PerkinElmer will work together with Sofie on the manufacturing and development of these new imaging instrument systems and assist Sofie in marketing Sofie’s chemical synthesis and advanced probe development capabilities.

These benchtop PET imaging systems provide highly sensitive and quantitative biological assays for application data in such fields as oncology, immunology, neurobiology, cardiology, and pharmacology. These systems are complementary to PerkinElmer’s current portfolio of preclinical offerings, which includes IVIS optical imaging systems (available with integrated x-ray or CT,), high-performance dedicated Quantum microCT systems and a full line of imaging reagents and probes, including PET radioisotopes.

In addition to the current G4 PET/X Ray system, PerkinElmer and Sofie are announcing a new translational imaging solution, the G8 PET/CT Small Animal Imaging System. This offering integrates PET and CT into an innovative, high-performance bench top system built to enable preclinical workflows for biologists, biochemists, and pharmacologists.

“As a leading provider of imaging platforms for cellular, tissue and in vivo research, PerkinElmer is pleased to partner with Sofie, a leader in the field of PET imaging, to deliver these systems to the global preclinical research community,” said Brian Kim, president, life sciences & technology, PerkinElmer. “In vivo preclinical imaging plays an integral role in translational research and drug discovery, facilitating a unique understanding of disease initiation, progression and therapeutic responses.”

“Our relationship combines PerkinElmer’s preclinical leadership with Sofie’s PET expertise to bring new translational imaging solutions to the global research community,” said Patrick Phelps, president and CEO of Sofie Biosciences.